MedTrace Logo

Post Marketing Surveillance Study on Emselex After Launch in Germany

NCT00786448 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5821

Last updated 2010-04-30

No results posted yet for this study

Summary

\- Data are obtained of Emselex in routine treatment of Overactive Bladder. The general objectives are to evaluate the product safety, compatibility, efficacy and patient acceptance.

Conditions

Interventions

DRUG

Darifenacin, Emselex (BAY79-4998)

Patients from routine practice

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2006-02-28
Completion
2006-02-28

Countries

  • Germany

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00786448 on ClinicalTrials.gov